Background：Vanucizumab RG7221 is an experimental humanized monoclonal antibody mAb designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 Ang2 and the other is based on bevacizumab Avastin, binding vascular endothelial growth factor A VEGF-A. The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors combination therapy, late-stage disease, metastatic disease, second-line therapy or greater in Spain, France, and Belgium.
